iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone on February 6, 2026, collecting 500 influenza swab samples in a few weeks to support a customer research project.

Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone on February 6, 2026, collecting 500 influenza swab samples in a few weeks to support a customer research project. The company also reports steady supply of cerebrospinal fluid (CSF) and rising demand for FFPE and fresh frozen tissue specimens. Customer feedback praised specimen quality and documentation for a 20-sample urine shipment and indicated intent to cite iSpecimen as the sample source in publications, underlining continued customer engagement and confidence.

Positive

• 500 influenza swabs procured in a few weeks
• Consistent supply of cerebrospinal fluid (CSF) for studies
• Growing client demand for FFPE and fresh frozen tissue
• Customer praised quality and documentation for 20 urine samples

Negative

• None.

Argus Feb 6 session

-4.38% close to close Open Argus

Details

News Market Reaction – ISPC

In the Feb 6 session, ISPC declined 4.38%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights operational strength: iSpecimen rapidly sourced 500 influenza swab samp...

Analysis

This announcement highlights operational strength: iSpecimen rapidly sourced 500 influenza swab samples, maintained cerebrospinal fluid supply, and reported rising demand for FFPE and fresh frozen tissues. In context, recent SEC filings show substantial registered resale capacity of 101,000,000 shares linked to a $5.5 million financing and weak Q3 2025 revenue of $106,592. Investors may watch execution on biospecimen demand, progress toward Nasdaq’s $1.00 bid requirement, and the pace of selling stockholder resales.

Key Figures

Influenza swab samples: 500 samples Urine samples: 20 samples Registered resale shares: 101,000,000 shares +5 more

Influenza swab samples

500 samples

Collected in a few weeks for a customer project

Urine samples

20 samples

Customer feedback cited high quality and documentation

Registered resale shares

101,000,000 shares

S-3 resale registration for Series C conversion shares

Potential shares outstanding

110,771,046 shares

If all Series C Conversion Shares are issued

Private placement proceeds

$5.5 million

Gross proceeds from December 2025 Series C financing

Q3 2025 revenue

$106,592

Quarter ended September 30, 2025

Prior-year Q3 revenue

$2,661,936

Quarter ended September 30, 2024

Q3 2025 net loss

$2,780,648

Quarter ended September 30, 2025

Historical Context

4 past events · Latest: Dec 30

4 events

1. Dec 30

   Private placement

   24h Move

   -13.2%

   Series C preferred stock financing expected to raise about $5.5M.

2. Sep 04

   Crypto treasury update

   24h Move

   +27.4%

   Update on pursuing $200M Solana-based corporate treasury reserve.

3. Aug 21

   Digital platform upgrade

   24h Move

   -29.8%

   Completion of Milestone 1 in Salestack-powered digital transformation.

4. Aug 07

   Crypto treasury launch

   24h Move

   -28.9%

   Announcement of $200M Solana-based corporate treasury with partners.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cerebrospinal fluid, csf, ffpe, fresh frozen

4 terms

cerebrospinal fluid medical

"In addition to respiratory specimens, iSpecimen continues to consistently maintain supply of cerebrospinal fluid (CSF)"

A clear fluid that surrounds and cushions the brain and spinal cord, acting like a protective bath and cleanup system that removes waste and helps circulate nutrients. For investors, cerebrospinal fluid matters because it is a common source of diagnostic markers and a route for delivering or testing neurological drugs; changes in its composition can signal disease or affect a therapy’s development, approval prospects, and market value.

csf medical

"maintain supply of cerebrospinal fluid (CSF) to support ongoing customer studies"

Cerebrospinal fluid (CSF) is the clear liquid that surrounds and cushions the brain and spinal cord, carrying nutrients and waste away from nervous tissue much like coolant and filters protect an engine. In clinical and regulatory news, CSF measurements are used to detect disease markers, track a drug’s effect on the central nervous system, or signal safety issues; changes in CSF test results can materially affect the perceived efficacy, market potential, and regulatory outlook for neuroscience-focused companies.

ffpe medical

"broader range of specimen types, including FFPE and fresh frozen (FF) tissue"

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

fresh frozen medical

"broader range of specimen types, including FFPE and fresh frozen (FF) tissue"

Fresh frozen describes biological material—most often blood plasma or tissue samples—that has been frozen soon after collection to preserve its natural components and prevent breakdown. For investors, it signals products or inventory that require strict temperature-controlled storage and handling, affecting operating costs, supply reliability and regulatory compliance much like perishable food kept in a freezer to remain usable and safe.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Lexington, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network.

Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected 500 influenza swab samples in just a few weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnaround and quality of the specimens have led to continued engagement with the customer in future respiratory sampling needs.

In addition to respiratory specimens, iSpecimen continues to consistently maintain supply of cerebrospinal fluid (CSF) to support ongoing customer studies. The company is also experiencing increased interest from clients seeking support across a broader range of specimen types, including FFPE and fresh frozen (FF) tissue, reflecting growing demand for reliable and diverse biospecimen sourcing.

Customer feedback continues to reinforce iSpecimen's commitment to quality and transparency. One recent customer shared:

"We were very excited upon receiving the urine specimens from iSpecimen and have begun to review all the information we received about the 20 samples. I must say that we are very impressed with their quality, and their extensive documentation."

The customer also indicated their intent to mention iSpecimen as the sample source in public discussions and publications, underscoring confidence in both specimen quality and accompanying documentation.

These accomplishments highlight iSpecimen's ongoing commitment to providing timely access to well-documented biospecimens that support critical research and scientific advancement.

About iSpecimen Inc.

iSpecimen Inc. (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

info@ispecimen.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282770

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How quickly did iSpecimen (ISPC) collect 500 influenza swab samples?

They collected 500 influenza swab samples in just a few weeks. According to the company, the rapid procurement supported a time-sensitive customer research project and led to continued engagement for future respiratory sampling needs.

Will iSpecimen (ISPC) continue supplying cerebrospinal fluid (CSF) for studies?

Yes, iSpecimen continues to maintain CSF supply for ongoing studies. According to the company, customers are receiving steady CSF access, which supports ongoing research continuity and study timelines.

What specimen types are clients increasingly requesting from iSpecimen (ISPC)?

Clients are requesting more FFPE and fresh frozen (FF) tissue samples beyond respiratory specimens. According to the company, this reflects rising demand for diverse, reliable biospecimen sourcing across multiple research modalities.

Did customers report satisfaction with iSpecimen (ISPC) sample quality and documentation?

Yes, at least one customer praised the quality and documentation for 20 urine samples. According to the company, the customer was impressed and plans to acknowledge iSpecimen as the sample source in publications.

What does the 500-sample influenza milestone mean for iSpecimen (ISPC) customers?

It demonstrates capacity for rapid, time-sensitive specimen procurement to support research needs. According to the company, the milestone led to continued customer engagement and confidence in timely access to well-documented biospecimens.